blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3630768

EP3630768 - (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  18.10.2021
Database last updated on 31.08.2024
FormerGrant of patent is intended
Status updated on  14.01.2021
FormerRequest for examination was made
Status updated on  06.03.2020
FormerThe international publication has been made
Status updated on  08.12.2018
Formerunknown
Status updated on  19.06.2018
Most recent event   Tooltip18.10.2021Application deemed to be withdrawnpublished on 17.11.2021  [2021/46]
Applicant(s)For all designated states
ESTEVE PHARMACEUTICALS, S.A.
Passeig de la Zona Franca, 109, 4ª Planta
08038 Barcelona / ES
[2020/15]
Inventor(s)01 / YENES-MINGUEZ, Susana
Passeig Terraplè 71
3°, 1a
08750 Molins de Rei Barcelona / ES
02 / FERNANDEZ-DONIS, Ariadna
c/ Enric Granados 107
08025 Barcelona / ES
03 / ALMANSA-ROSALES, Carmen
c/ Teodora Lamadrid 41
08022 Barcelona / ES
 [2020/15]
Application number, filing date18729367.529.05.2018
[2020/15]
WO2018EP64037
Priority number, dateEP2017038231030.05.2017         Original published format: EP 17382310
[2020/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018219927
Date:06.12.2018
Language:EN
[2018/49]
Type: A1 Application with search report 
No.:EP3630768
Date:08.04.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 06.12.2018 takes the place of the publication of the European patent application.
[2020/15]
Search report(s)International search report - published on:EP06.12.2018
ClassificationIPC:C07D487/04, A61K31/4985, A61P25/04
[2020/15]
CPC:
C07D487/04 (EP,US); A61P25/04 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/15]
TitleGerman:(HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINDERIVATE MIT MULTIMODALER AKTIVITÄT GEGEN SCHMERZEN[2021/01]
English:(HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN[2020/15]
French:DERIVES DE (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE AVEC ACTIVITE MULTIMODALE CONTRE DOULEUR[2021/01]
Former [2020/15](HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZIN-DERIVATE MIT MULTIMODALER AKTIVITÄT GEGEN SCHMERZEN
Former [2020/15]DÉRIVÉS D'(HÉTÉRO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE AYANT UNE ACTIVITÉ MULTIMODALE CONTRE LA DOULEUR
Entry into regional phase02.01.2020National basic fee paid 
02.01.2020Designation fee(s) paid 
02.01.2020Examination fee paid 
Examination procedure02.01.2020Examination requested  [2020/15]
02.01.2020Date on which the examining division has become responsible
13.07.2020Amendment by applicant (claims and/or description)
15.01.2021Communication of intention to grant the patent
26.05.2021Application deemed to be withdrawn, date of legal effect  [2021/46]
01.07.2021Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2021/46]
Fees paidRenewal fee
02.06.2020Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.05.202104   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]  - MYATT JAMES W ET AL, "Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (20100531), vol. 20, no. 15, doi:10.1016/J.BMCL.2010.05.026, ISSN 0960-894X, pages 4683 - 4688, XP029121111 [I] 1-13 * Compounds in Table 1; fitst column on page 4684 last two paragraphs and second comumn on page 4684 fist paragraph; *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2010.05.026
by applicant   - TURK, D.C.; WILSON, H.D.; CAHANA, A., Lancet, (20110000), vol. 377, pages 2226 - 2235
    - GOLDBERG, D.S.; MCGEE, S.J., BMC Public Health, (20110000), vol. 11, page 770
    - ZAMPONI et al., Pharmacol. Rev., (20150000), vol. 67, pages 821 - 70
    - PERRET; LUO, Neurotherapeutics, (20090000), vol. 6, pages 679 - 92
    - NEUMAIER et al., Prog. Neurobiol., (20150000), vol. 129, pages 1 - 36
    - VINK; ALEWOOD, Br J Pharmacol., (20120000), vol. 167, pages 970 - 89
    - DAVIES et al., Trends Pharmacol Sci., (20070000), vol. 28, pages 220 - 8
    - DOLPHIN AC, Nat Rev Neurosci., (20120000), vol. 13, pages 542 - 55
    - Biochim Biophys Acta, (20130000), vol. 1828, pages 1541 - 9
    - MASON,S.T., Prog. Neurobiol., (19810000), vol. 16, pages 263 - 303
    - KASPER et al., Expert Opin. Pharmacother., (20000000), vol. 1, pages 771 - 782
    - OSSIPOV et al., J. Clin. Invest., (20100000), vol. 120, pages 3779 - 3787
    - WANG et al., J. Pain, (20130000), vol. 14, pages 845 - 853
    - CHABOT-DORE et al., Neuropharmacology, (20150000), vol. 99, pages 285 - 300
    - FAIRBANKS et al., Pharmacol. Ther., (20090000), vol. 123, pages 224 - 238
    - MOCHIZUCKI,D., Psychopharmacol, (20040000), pages S15 - S19
    - HARTRICK,C.T., Expert Opin. Investig. Drugs, (20120000), vol. 21, pages 1827 - 1834
    - LEHAR et al., Nat. Biotechnol., (20090000), vol. 27, pages 659 - 666
    - GILRON et al., Lancet Neurol., (20131100), vol. 12, no. 11, pages 1084 - 95
    - SCHRODER et al., J Pharmacol. Exp. Ther., (20110000), vol. 337, pages 312 - 20
    - J Pharmacol. Exp. Ther., (20120000), vol. 342, page 232
    - ZHANG et al., Cell Death Dis., (20140000), vol. 5, page e1138
    - HOPKINS, Nat. Chem. Biol., (20080000), vol. 4, pages 682 - 90
    - NICOLSON et al., Harv. Rev. Psychiatry, (20090000), vol. 17, pages 407 - 420
    - HAYASHIDA,K., Eur. J. Pharmacol., (20080000), vol. 598, pages 21 - 26
    - MIRANDA,H.F. et al., J. Orofac. Pain, (20130000), vol. 27, pages 361 - 366
    - Pharmacology, (20150000), vol. 95, pages 59 - 64
    - FRAMPTON,J.E., CNS Drugs, (20140000), vol. 28, pages 835 - 854
    - HAJOS,M. et al., CNS Drug Rev., (20040000), vol. 10, pages 23 - 44
    - MAO, J.; GOLD, M.S.; BACKONJA, M., J. Pain, (20110000), vol. 12, pages 157 - 166
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.